What KPV adds to a repair stack, and what we still do not know

Where KPV comes from

Alpha-melanocyte-stimulating hormone (alpha-MSH) is best known for its role in skin pigmentation, but it also helps calm inflammation. Researchers found that much of this anti-inflammatory activity could be traced to the last three amino acids of the molecule: lysine, proline and valine, abbreviated KPV.

Because KPV is so small, it does not appear to act on the melanocortin receptors that drive pigmentation in the same way the full hormone does. That made it interesting as a possible anti-inflammatory without tanning effects.

What the research has looked at

Most studies have been in cells and mice, particularly models of inflammatory bowel disease. In those experiments, KPV was taken up by intestinal cells through a peptide transporter called PepT1, which is more active in inflamed gut tissue, and it dampened inflammatory pathways such as NF-kB. Mice with chemically induced colitis had less inflammation when given KPV.

Other work has focused on delivery, such as packaging KPV in nanoparticles or gels to reach inflamed tissue, and a smaller body of research has explored skin inflammation. These are early laboratory steps.

The case for adding it to a stack

BPC-157 and TB-500 are studied for signals linked to tissue repair, blood vessel growth and cell migration, mainly in animals. The reasoning behind adding KPV is that excessive or prolonged inflammation can slow recovery, so calming it might help repair peptides do their work.

That reasoning is a hypothesis. No study has tested KPV alongside BPC-157 and TB-500, and combining compounds can change how each behaves. Inflammation is also a normal and necessary part of healing; suppressing it is not automatically helpful, especially in the early days after an injury.

What is missing from the evidence

• No published randomized controlled trial of KPV in people for any condition
• No human exposure data identified by the FDA for any route
• No studies of KPV injected under the skin for musculoskeletal recovery
• No data on long-term safety, drug interactions or effects in older adults
• No research on KPV in combination stacks

How to judge whether the stack is helping

If you and your clinician decide to try the stack, agree on concrete measures before you start, such as pain scores during a specific movement, how far you can walk or lift without a flare, or how many days you need pain relievers. Keep doing the rehabilitation exercises your physical therapist or clinician recommends, because they have the strongest evidence for most injuries. Review progress at a set point. Because three compounds are given together, it is impossible to know which one, if any, made a difference, and natural healing over the same weeks is a major confounder.

KPV is not a treatment for inflammatory bowel disease

Because most KPV research involves colitis models, it is sometimes promoted for ulcerative colitis or Crohn's disease. Inflammatory bowel disease needs proven, specialist-led care. NIDDK describes established treatments including aminosalicylates, corticosteroids, immunosuppressants, biologics and newer small-molecule medicines, chosen according to severity, and advises checking with your doctor before taking supplements.

If you have IBD, do not replace or delay standard treatment with KPV or any peptide. Tell your gastroenterologist about anything you are considering.

Regulatory status as of October 2026

KPV is not FDA-approved. It was previously in Category 2 of the FDA's interim lists of bulk substances for compounding, and in April 2026 its nomination was withdrawn, moving it to the nominated-but-withdrawn list. That was not a safety finding and did not place KPV in Category 1. In its safety review, the FDA noted it had identified no human exposure data for KPV and that important safety information is lacking.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend KPV for the 503A bulks list for proposed uses in wound healing and inflammatory conditions. FDA staff had recommended against it. The vote is advisory and non-binding; the FDA must still complete notice-and-comment rulemaking, and no final action had been taken as of October 2026.

Safety screening before anything is prescribed

• Current or past cancer, since repair and growth signals are a theoretical concern with stack components
• Pregnancy or breastfeeding, for which there are no data
• Autoimmune or inflammatory bowel disease, which needs specialist care
• Competitive sport, because many peptides are prohibited under anti-doping rules
• All medicines and supplements, including other peptides

The Repair & Recovery Stack through HealifyMD

A HealifyMD clinician reviews your injury, gut history, cancer history, medicines and sport participation before discussing the stack, and prescribes only when appropriate and only if a licensed pharmacy confirms it can lawfully dispense it. The stack is a compounded preparation from a licensed U.S. pharmacy; compounded medicines are not FDA-approved, and we do not publish home dosing. The price is from $300/month, confirmed at your eligibility review.